Segui
Fredrik Piehl
Fredrik Piehl
Professor of neurology, Karolinska Institutet
Email verificata su ki.se
Titolo
Citata da
Citata da
Anno
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
Nature 476 (7359), 214-219, 2011
29542011
Neurofilaments as biomarkers in neurological disorders
M Khalil, CE Teunissen, M Otto, F Piehl, MP Sormani, T Gattringer, ...
Nature Reviews Neurology 14 (10), 577-589, 2018
14622018
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
International IBD Genetics Consortium (IIBDGC), C Agliardi, L Alfredsson, ...
Nature genetics 45 (11), 1353-1360, 2013
13232013
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
International Multiple Sclerosis Genetics Consortium*†, ANZgene, ...
Science 365 (6460), eaav7188, 2019
8382019
Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 control subjects via the enhancing neuro imaging genetics through meta analysis (ENIGMA) consortium
TGM Van Erp, E Walton, DP Hibar, L Schmaal, W Jiang, DC Glahn, ...
Biological psychiatry 84 (9), 644-654, 2018
7002018
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind …
JF Howard, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ...
The Lancet Neurology 16 (12), 976-986, 2017
5752017
Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis
C Bridel, WN Van Wieringen, H Zetterberg, BM Tijms, CE Teunissen, ...
JAMA neurology 76 (9), 1035-1048, 2019
5392019
Risk factors for amyotrophic lateral sclerosis
C Ingre, PM Roos, F Piehl, F Kamel, F Fang
Clinical epidemiology, 181-193, 2015
5222015
Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies
G Luna, P Alping, J Burman, K Fink, A Fogdell-Hahn, M Gunnarsson, ...
JAMA neurology 77 (2), 184-191, 2020
4292020
Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis
I Jelcic, F Al Nimer, J Wang, V Lentsch, R Planas, I Jelcic, A Madjovski, ...
Cell 175 (1), 85-100. e23, 2018
4152018
MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction
M Swanberg, O Lidman, L Padyukov, P Eriksson, E Åkesson, M Jagodic, ...
Nature genetics 37 (5), 486-494, 2005
4112005
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab
M Gunnarsson, C Malmeström, M Axelsson, P Sundström, C Dahle, ...
Annals of neurology 69 (1), 83-89, 2011
3902011
Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
L Novakova, H Zetterberg, P Sundström, M Axelsson, M Khademi, ...
Neurology 89 (22), 2230-2237, 2017
3892017
Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells
H Hammarberg, O Lidman, C Lundberg, SY Eltayeb, AW Gielen, ...
Journal of Neuroscience 20 (14), 5283-5291, 2000
3732000
Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy
J Salzer, R Svenningsson, P Alping, L Novakova, A Björck, K Fink, ...
Neurology 87 (20), 2074-2081, 2016
3712016
Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study
J Kuhle, G Disanto, R Dobson, R Adiutori, L Bianchi, J Topping, ...
Multiple Sclerosis Journal 21 (8), 1013-1024, 2015
3672015
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open …
R Kapoor, PR Ho, N Campbell, I Chang, A Deykin, F Forrestal, N Lucas, ...
The Lancet Neurology 17 (5), 405-415, 2018
3232018
T Cell Ig-and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived …
M Khademi, Z Illés, AW Gielen, M Marta, N Takazawa, C Baecher-Allan, ...
The Journal of Immunology 172 (11), 7169-7176, 2004
3152004
Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course
M Khademi, I Kockum, ML Andersson, E Iacobaeus, L Brundin, ...
Multiple Sclerosis Journal 17 (3), 335-343, 2011
2982011
A role for MHC class I molecules in synaptic plasticity and regeneration of neurons after axotomy
ALR Oliveira, S Thams, O Lidman, F Piehl, T Hökfelt, K Kärre, H Lindå, ...
Proceedings of the National Academy of Sciences 101 (51), 17843-17848, 2004
2942004
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20